Singapore markets closed

BiomX Inc. (PHGE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.3550-0.0011 (-0.30%)
As of 10:22AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.3561
Open0.3700
Bid0.3500 x 1800
Ask0.3564 x 1300
Day's range0.3500 - 0.3700
52-week range0.1870 - 0.8550
Volume56,219
Avg. volume2,675,109
Market cap16.35M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)-0.6300
Earnings date03 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, April 3rd, 2024, at 8:00 a.m. ET, to report fourth quarter and full year 2023 financial results and a provide business update. To participate

  • GlobeNewswire

    BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

    Acquisition creates leading phage therapy company with an advanced pipeline that includes two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”) Financing of $50 million will be used to advance the two lead product candidates through Phase 2 clinical readouts in 2025 CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE)

  • GlobeNewswire

    BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

    Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”) Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive agreement for a private placement financing of $50 million that will be used to advance two lead product candidates through Phase 2 clinical readout